Statin use is linked to better survival in breast cancer, observational data from Taiwan suggest. Yet researchers only saw a difference for all-cause and cancer-related deaths, not CV death. The ...

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. It’s a math problem with life-and-death ...

Statins are known to be associated with increased insulin resistance and higher blood glucose levels, but now a new observational study demonstrates that these metabolic changes translate into ...

EAST HANOVER, N.J., April 6, 2024 /PRNewswire/ -- Novartis today announced new data demonstrating the early addition of twice-yearly* Leqvio ® (inclisiran) to maximally tolerated statin therapy, prior ...

Statins, which are prescription drugs that can reduce cholesterol levels and lower the risk for heart disease, don’t affect kidney function, new research shows. Investigators found that taking a ...

Evidence supporting the use of statins to protect against cardiotoxic chemotherapy has been strengthened with new data from a propensity-matched analysis. Among women with breast cancer treated with ...

The polypill offers a cost-effective solution for CVD management in underserved populations, potentially reducing health disparities. The intervention is projected to cost $8560 per QALY gained, ...

March 31, 2011 (San Francisco) — A new analysis of three major trials with atorvastatin (Lipitor, Pfizer) has suggested that the risk of new-onset diabetes with statins appears to be dose dependent ...

– Findings were shared at the National Lipid Association Scientific Sessions – ANN ARBOR, Mich., June 03, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced findings from a real-world analysis ...

2024 NOV 29 (NewsRx) -- By a News Reporter-Staff News Editor at Health Policy and Law Daily-- Fresh data on Managed Care are presented in a new report. According to news reporting originating from ...

SILVER SPRING, Md., Dec 13 (Reuters) - A Merck & Co Inc study failed to show that consumers could make appropriate decisions about whether to take a proposed over-the-counter version of cholesterol ...